233 related articles for article (PubMed ID: 35410412)
1. The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
Lim B; Yoo D; Chun Y; Go A; Cho KJ; Choi D; Jung ME; Lee HY; Boohaker RJ; Lee JS; Jung D; Choi G
Blood Cancer J; 2022 Apr; 12(4):57. PubMed ID: 35410412
[No Abstract] [Full Text] [Related]
2. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Badar T; Nanaa A; Atallah E; Shallis RM; Guilherme SCC; Goldberg AD; Saliba AN; Patel A; Bewersdorf JP; DuVall AS; Bradshaw D; Abaza Y; Murthy GSG; Palmisiano N; Zeidan AM; Kota V; Litzow MR
Blood Cancer J; 2024 Feb; 14(1):32. PubMed ID: 38378617
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Ferrara F
Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
[No Abstract] [Full Text] [Related]
4. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia.
Kennedy VE; Hui G; Azenkot T; Gaut D; Wieduwilt MJ; Oliai C; Jonas BA; Mittal V; Logan AC; Muffly LS; Mannis GN
Am J Hematol; 2022 Jun; 97(6):E191-E194. PubMed ID: 35266185
[No Abstract] [Full Text] [Related]
5. Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
Gangat N; Tefferi A
Am J Hematol; 2024 Apr; 99(4):515-518. PubMed ID: 38375926
[TBL] [Abstract][Full Text] [Related]
6. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia.
Gangat N; Johnson I; McCullough K; Farrukh F; Al-Kali A; Alkhateeb H; Begna K; Mangaonkar A; Litzow M; Hogan W; Shah M; Patnaik M; Pardanani A; Tefferi A
Haematologica; 2022 Oct; 107(10):2501-2505. PubMed ID: 35770533
[No Abstract] [Full Text] [Related]
7. Venetoclax in acute myeloid leukemia.
Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Investig Drugs; 2023 Apr; 32(4):271-276. PubMed ID: 36933006
[No Abstract] [Full Text] [Related]
8. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.
Bewersdorf JP; Giri S; Wang R; Williams RT; Tallman MS; Zeidan AM; Stahl M
Haematologica; 2020 Nov; 105(11):2659-2663. PubMed ID: 33131256
[No Abstract] [Full Text] [Related]
9. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
[No Abstract] [Full Text] [Related]
10. Hypomethylating agents and venetoclax in acute myeloid leukemia.
DiNardo CD
Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188
[No Abstract] [Full Text] [Related]
11. Hypomethylating agents with venetoclax: have we discovered the holy grail?
Gutman JA; Pollyea DA
Curr Opin Hematol; 2020 Mar; 27(2):76-80. PubMed ID: 31895103
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
Ball BJ; Arslan S; Koller P; Ngo D; Afkhami M; Salhotra A; Al-Malki M; Aribi A; Ali H; Sandhu K; Otoukesh S; Amanam I; Pourhassan H; Artz A; Curtin P; Stein A; Nakamura R; Marcucci G; Smith E; Pullarkat V; Aldoss I
Leuk Lymphoma; 2022 Dec; 63(13):3232-3236. PubMed ID: 36089918
[No Abstract] [Full Text] [Related]
13. Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
Nachmias B; Aumann S; Haran A; Schimmer AD
Br J Haematol; 2024 Apr; 204(4):1146-1158. PubMed ID: 38296617
[TBL] [Abstract][Full Text] [Related]
14. Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
Jamy O; Lin K; Worth S; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R
Br J Haematol; 2022 Aug; 198(3):e35-e37. PubMed ID: 35509246
[No Abstract] [Full Text] [Related]
15. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
16. Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
Niscola P; Gianfelici V; Giovannini M; Piccioni D; Mazzone C; Fabritiis P
Ann Hematol; 2024 May; 103(5):1787-1788. PubMed ID: 38459155
[No Abstract] [Full Text] [Related]
17. Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
Salhotra A; Tsai NC; Zhang J; Ngo D; Aribi A; Sandhu K; Ball B; Al-Malki M; Ali H; Koller P; Artz A; Forman S; Nakamura R; Stein A; Marcucci G; Aldoss I; Pullarkat V
Br J Haematol; 2022 Mar; 196(6):e71-e74. PubMed ID: 34931310
[No Abstract] [Full Text] [Related]
18. Toward an improved understanding of hypomethylating agent and venetoclax therapies.
DiNardo CD
Am J Hematol; 2024 Feb; 99(2):152-154. PubMed ID: 38102772
[No Abstract] [Full Text] [Related]
19. Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?
Pollyea DA; Jordan CT
Curr Opin Hematol; 2019 Mar; 26(2):71-76. PubMed ID: 30652974
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Aldoss I; Yang D; Aribi A; Ali H; Sandhu K; Al Malki MM; Mei M; Salhotra A; Khaled S; Nakamura R; Snyder D; O'Donnell M; Stein AS; Forman SJ; Marcucci G; Pullarkat V
Haematologica; 2018 Sep; 103(9):e404-e407. PubMed ID: 29545346
[No Abstract] [Full Text] [Related]
[Next] [New Search]